By Fineline Cube Full-Life Technologies Limited announced that its Investigational New Drug (IND) application for [²²⁵Ac]Ac‑FL‑261 has been cleared by the U.S. Food and Drug Administration (FDA), enabling clinical trials of the potential first‑in‑class c‑MET‑targeting alpha radionuclide conjugate (RDC). In parallel, the program has received approval from Australia’s Human Research Ethics Committee (HREC) and completed procedures for a Clinical Trial Notification (CTN) filing with the Therapeutic Goods Administration (TGA). The company will initiate a Phase I clinical trial in the United States and Australia for patients with c‑MET‑overexpressing non‑squamous non‑small cell lung cancer (nsNSCLC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency (U.S.) | Food and Drug Administration (FDA) |
| Clearance Type | IND clearance to proceed with clinical trials |
| Agency (Australia) | HREC ethics approval granted; CTN procedures completed for TGA |
| Product | [²²⁵Ac]Ac‑FL‑261 (actinium‑225 alpha‑emitting RDC) |
| Indication | c‑MET‑overexpressing non‑squamous non‑small cell lung cancer (nsNSCLC) |
| Announcement Date | 9 Sep 2026 |
| Next Steps | Phase I first‑in‑human trial across U.S. and Australian sites |
Drug Profile & Mechanism of Action
- Molecule: [²²⁵Ac]Ac‑FL‑261, an investigational alpha radionuclide conjugate labeled with actinium‑225 (²²⁵Ac), a high‑energy alpha emitter.
- Target: c‑MET (mesenchymal‑epithelial transition factor), a receptor tyrosine kinase overexpressed in multiple solid tumors and associated with aggressive disease and poor prognosis.
- Mechanism: The conjugate is designed to selectively bind c‑MET‑overexpressing tumor cells and deliver alpha‑particle radiation directly to the tumor, producing highly cytotoxic, short‑range double‑strand DNA damage while sparing surrounding healthy tissue.
- Innovation: Positioned as a potential first‑in‑class c‑MET‑targeted alpha RDC — a modality not yet represented among approved c‑MET‑directed therapies, which today comprise small‑molecule inhibitors, antibodies, and antibody–drug conjugates.
- Platform: FL‑261 is one of several radiopharmaceutical assets discovered on Full‑Life Technologies’ proprietary UniRDC drug discovery platform, underscoring the platform’s ability to generate clinically viable conjugates.
- Development Scope: Being advanced for multiple solid tumor indications, with nsNSCLC as the lead Phase I population.
Phase I Trial Framework – United States & Australia
- Design: First‑in‑human Phase I study of [²²⁵Ac]Ac‑FL‑261; dose escalation and safety characterization are typical objectives at this stage. Specific endpoints: Not disclosed.
- Geography: Dual‑jurisdiction enrollment across the U.S. (FDA IND cleared) and Australia (HREC approval granted; CTN route completed with the TGA), a strategy that can accelerate site activation and patient recruitment.
- Population: Patients with c‑MET‑overexpressing nsNSCLC, a subset of non‑squamous NSCLC with limited targeted treatment options once standard therapies fail.
- Timing & size: Enrollment start date, site count, and sample size: Data not yet disclosed.
Market Impact & Outlook
- Radiopharmaceutical Momentum: Alpha‑emitting RDCs represent one of the fastest‑moving frontiers in oncology drug development, building on the commercial validation of the broader radioligand therapy class; FL‑261 positions Full‑Life Technologies within the emerging alpha‑emitter cohort.
- First‑Mover Positioning: As a potential first‑in‑class c‑MET RDC, FL‑261 could establish a differentiated therapeutic modality for c‑MET‑overexpressing solid tumors, complementing — rather than directly competing with — existing c‑MET inhibitors and ADCs.
- Platform Validation: Regulatory clearance of a UniRDC‑derived asset provides external validation of the company’s proprietary discovery engine and its multi‑asset radiopharmaceutical pipeline.
- Transparency: Commercialization timelines, partnership plans, and funding details were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical trial initiation and outcomes, and development expectations for [²²⁵Ac]Ac‑FL‑261. Actual results may differ materially due to risks including clinical safety and efficacy findings, further regulatory requirements in the U.S. and Australia, enrollment pace, and competitive dynamics in the radiopharmaceutical sector.-Fineline Info & Tech